If Kerendia secures a label expansion, it would become available to more than half of the overall CKD patient population who ...

Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD). Extending the label for Kerendia is a strategic priority for ...

The current kidney care model—focused on late-stage disease and in-center hemodialysis—is unsustainable, because of costs, environmental burden, poor outcomes, and reduced quality of life.